Trials / Conditions / Healthy Study Participants

Healthy Study Participants

15 registered clinical trials studyying Healthy Study Participants — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, NCT06970301	UCB Biopharma SRL	Phase 1
Completed	A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants NCT06679413	UCB BIOSCIENCES, Inc.	Phase 1
Completed	A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study NCT06312566	UCB Biopharma SRL	Phase 1
Completed	A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to T NCT05845645	UCB Biopharma SRL	Phase 1
Completed	A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study NCT05315947	UCB Biopharma SRL	Phase 1
Completed	A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in NCT05292131	UCB Biopharma SRL	Phase 1
Completed	A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants NCT04867642	UCB Biopharma SRL	Phase 1
Completed	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Admini NCT04828343	UCB Biopharma SRL	Phase 1
Completed	A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Parti NCT04802746	UCB Biopharma SRL	Phase 1
Completed	Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chi NCT04782388	UCB Biopharma SRL	Phase 1
Completed	A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous D NCT04705350	UCB Biopharma SRL	Phase 1
Terminated	A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Partici NCT04444466	UCB Biopharma SRL	Phase 1
Terminated	A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Health NCT04255862	UCB Biopharma SRL	Phase 1
Terminated	A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic NCT04136444	UCB Biopharma S.P.R.L.	Phase 1
Terminated	A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants NCT04126343	UCB Biopharma S.P.R.L.	Phase 1